A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2019
Price : $35 *
At a glance
- Drugs Amantadine (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms ALLAY-LID II
- Sponsors Osmotica Pharmaceutical
- 31 Aug 2018 Biomarkers information updated
- 15 Feb 2018 Status changed from recruiting to discontinued.
- 18 Jun 2016 This trial was Temporarily Halted in Spain.